A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
NCT06208124
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor (Phase 1)
Pancreas Adenocarcinoma
Non-small Cell Lung Cancer
Malignant Melanoma (Cutaneous)
Interventions
DRUG:
IMM-6-415
Sponsor
Immuneering Corporation